Deutsche Bank initiated coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report published on Thursday morning, Benzinga reports. The firm issued a buy rating and a $42.00 price objective on the stock.
Other research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of General Finance from a buy rating to a hold rating in a research note on Monday, July 15th. ValuEngine lowered shares of Woodward, Inc.Common Stock from a buy rating to a hold rating in a research note on Tuesday, April 9th. Piper Jaffray Companies lowered shares of Cypress Semiconductor from an overweight rating to a neutral rating in a research note on Monday, June 3rd. Finally, BidaskClub lowered shares of Weyco Group from a sell rating to a strong sell rating in a research note on Saturday, July 13th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $41.00.
NASDAQ DCPH opened at $20.65 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.55 and a quick ratio of 9.55. The stock’s 50 day moving average price is $22.74. Deciphera Pharmaceuticals has a 52 week low of $18.55 and a 52 week high of $41.00.
In other Deciphera Pharmaceuticals news, CFO Thomas Patrick Kelly sold 2,100 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $25.20, for a total transaction of $52,920.00. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders have sold 17,250 shares of company stock worth $403,813. 7.02% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA grew its position in Deciphera Pharmaceuticals by 61,033.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after purchasing an additional 1,831 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in Deciphera Pharmaceuticals during the 4th quarter worth approximately $50,000. Rhumbline Advisers grew its position in Deciphera Pharmaceuticals by 53.6% during the 4th quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after purchasing an additional 4,000 shares during the last quarter. Barclays PLC grew its position in Deciphera Pharmaceuticals by 187.7% during the 4th quarter. Barclays PLC now owns 13,908 shares of the company’s stock worth $292,000 after purchasing an additional 9,073 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Deciphera Pharmaceuticals by 1,506.1% during the 4th quarter. Bank of America Corp DE now owns 23,561 shares of the company’s stock worth $494,000 after purchasing an additional 22,094 shares during the last quarter. 58.89% of the stock is currently owned by institutional investors.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Recommended Story: Why do companies issue convertible shares?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.